Evexia Wealth Trims Eli Lilly Stake

Investment firm reduces holding in pharmaceutical giant by 5.3%

Apr. 6, 2026 at 8:04am

Got story updates? Submit your updates here. ›

Evexia Wealth LLC, a financial advisory firm, lowered its position in shares of Eli Lilly and Company (NYSE: LLY) by 5.3% in the fourth quarter, according to a recent SEC filing. The firm now owns 20,481 shares of the pharmaceutical company's stock, valued at $21,982,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines. Tracking institutional investor activity in Lilly's stock can provide insights into market sentiment and the overall health of the company.

The details

In its 13F filing, Evexia Wealth reported selling 1,147 shares of Eli Lilly during the fourth quarter. The firm's total holding in Lilly now represents 6.3% of its investment portfolio, making it the firm's largest position. Several other hedge funds and institutional investors have also adjusted their Lilly positions in recent quarters.

  • Evexia Wealth filed its 13F report for the fourth quarter of 2025 on April 6, 2026.

The players

Evexia Wealth LLC

A financial advisory firm that manages investments for its clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Institutional investors like Evexia Wealth closely monitor the performance and prospects of major pharmaceutical companies like Eli Lilly. While a 5.3% reduction in Evexia's Lilly position is relatively minor, it could signal a shift in the firm's outlook on the stock or the broader industry.